Rubin R L, Nusinow S R, Johnson A D, Rubenson D S, Curd J G, Tan E M
Am J Med. 1986 May;80(5):999-1002. doi: 10.1016/0002-9343(86)90653-4.
Procainamide-induced lupus is a well-recognized syndrome, but the events leading up to clinical symptoms are obscure. In the present study, serologic changes in a 69-year-old man were monitored during his treatment with procainamide and after discontinuation of procainamide because of symptoms of drug-induced lupus. Antihistone antibodies of unique specificity and in vivo complement activation were detected after one year of procainamide therapy during a period prior to development of significant clinical symptoms. Antihistone antibodies and complement activation substantially increased during a full-blown episode of lupus-like symptoms. Progressive return to normal laboratory findings occurred after procainamide was discontinued. The antihistone/complement profile may be useful in the diagnosis of drug-induced lupus and warn of impending clinical deterioration in patients with minimal symptoms.
普鲁卡因胺诱发的狼疮是一种公认的综合征，但导致临床症状出现的过程尚不清楚。在本研究中，对一名69岁男性在接受普鲁卡因胺治疗期间以及因药物性狼疮症状停用普鲁卡因胺后进行了血清学变化监测。在普鲁卡因胺治疗一年后，在出现明显临床症状之前的一段时间内检测到了具有独特特异性的抗组蛋白抗体和体内补体激活。在狼疮样症状全面发作期间，抗组蛋白抗体和补体激活显著增加。停用普鲁卡因胺后，实验室检查结果逐渐恢复正常。抗组蛋白/补体谱可能有助于药物性狼疮的诊断，并对症状轻微的患者即将出现的临床恶化发出警告。
